Psychedelic Bulletin #141: Terran’s 4-OH-DiPT Prodrug Patent App.; Generic Ketamine Appears Effective for TRD; VA/DoD Guideline Reviews Psychedelics

This Week: and lots more… Reporting by Noah Smith1 Here, we explore the latest twist in the battle over 4-OH-DiPT2 prodrug patents as a new player enters the fold: Terran Biosciences. Earlier this year we provided analysis of a lawsuit filed by Reunion Neuroscience (which was formerly part of Field Trip) against its competitor, Mindset Pharma. In its complaint (PDF), Reunion asserted that Mindset…

Source